Last edition
News about "AbbVie"
AbbVie and REGENXBIO Update on ABBV-RGX-314 Clinical Program
AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector® to deliver gene therapy to the suprachoroidal space of the eye.
AbbVie | 15/01/2025 | By Aishwarya
AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline
AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.
AbbVie | 18/12/2024 | By Aishwarya
AbbVie Announces Acquisition of Aliada Therapeutics
Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial.
AbbVie | 13/12/2024 | By Aishwarya
AbbVie Receives European Commission Approval of ELAHERE
ELAHERE is the first and only folate receptor alpha (FR?)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland.
AbbVie | 18/11/2024 | By Aishwarya
AbbVie and EvolveImmune to Develop Next-Gen Cancer Biotherapeutics
EvolveImmune's proprietary EVOLVE platform is designed to deliver potent, selective and integrated T-cell co-stimulation to amplify and sustain the tumor killing capacity of the T-cells.
AbbVie | 01/11/2024 | By Aishwarya
AbbVie and Gedeon Richter to Develop Novel Targets for Neuropsychiatric Conditions
This collaboration expands upon the success of nearly two decades of partnership on central nervous system (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA) and the discovery of investigational drug candidate ABBV-932 for the treatment of bipolar depression and generalized anxiety disorder.
AbbVie | 25/10/2024 | By Aishwarya
AbbVie Submits BLA to FDA for Teliso-V in Previously Treated Non-Small Cell Lung Cancer
AbbVie has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V).
AbbVie | 30/09/2024 | By Aishwarya | 124
AbbVie Gets Positive CHMP Opinion for Mirvetuximab Soravtansine
AbbVie has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE).
AbbVie | 21/09/2024 | By Aishwarya | 112
AbbVie Completes Acquisition of Cerevel Therapeutics
AbbVie has announced the completion of its acquisition of Cerevel Therapeutics.
AbbVie | 02/08/2024 | By Aishwarya
Sionna Signs License Agreement with AbbVie for Clinical Stage Compounds
Sionna Therapeutics has secured exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds through a license agreement with AbbVie.
AbbVie | 30/07/2024 | By Aishwarya | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy